期刊文献+

CA199联合ERCP对胰胆管恶性肿瘤的诊断价值研究 被引量:1

The Study about Diagnostic Value of CA199 Combined with ERCP to Pancreaticobiliary Malignant Tumors
在线阅读 下载PDF
导出
摘要 目的研究CA19—9对胆道和胰腺恶性肿瘤的诊断价值,以及胆总管梗阻对CA19—9值的影响。方法首先回顾性分析168例胆道和胰腺疾病的患者血清CA199对胆道和胰腺恶性肿瘤的诊断价值。然后前瞻性地对54例因胆总管梗阻而行ERCP+胆总管支架植入术的患者进行研究。结果胆道和胰腺恶性肿瘤组CA199水平明显高于良性疾病组,差异具有统计学意义(P<0.01)。血清CA199对胰腺和胆道恶性肿瘤诊断的敏感性分别为100%和84%,特异性分别为87.27%和53.16%。在ERCP术前CA199对胆总管恶性梗阻的诊断的特异性只有43.48%,而在ERCP术后上升到86.96%。结论 CA199对胰腺和胆道恶性肿瘤具有较高的诊断价值,尤其是解除胆道梗阻以后其诊断恶性肿瘤的特异性显著升高。 Objective: To study the diagnostic value of CA199 to malignant tumors of pancreaticobiliary and the influence of common bile duct obstruction to CA19-9 levels. Method: First of all, we collected 168 cases of clinical data of patients with biliary and pancreatic diseases, and retrospectively analyzed the diagnostic value of serum CA199 in patients with biliary and pancreatic malignancies. Then, we carried out a prospective study including 54 cases of patients with common bile duct obstruction. In this project, we studied the influence of ERCP and common bile duct stent implantation to CA199 levels and analyzed the diagnostic value of CA199 combined with ERCP to malignant obstruction of bile duct. Result: The retrospective data showed that CA199 levels ofbiliary and pancreatic malignant tumor group were significantly higher than those of benign disease group (P 〈0.01) , the sensitivity of CA19-9 to malignant tumors of pancreas and biliary were 84% and 100% and the specificity 87.27% and 53.16% respectively. The prospective data showed that specificity of CA199 to bile duct malignant obstruction was only 43.48% before the ERCP and common bile duct stent implantation and the specificity rised to 86.96% after the operation. Conclusion: CA199 has a high diagnostic value to pancreatic and biliary tract malignancies, especially to biliary obstruction after the ERCP and common bile duct stent implantation operation.
出处 《西藏医药》 2014年第4期8-11,共4页 Tibetan Medicine
关键词 胆胰 恶性肿瘤 诊断 ERCP CA199 Pancreaticobiliary Malignancies Diagnosis ERCP Ca199
  • 相关文献

参考文献3

二级参考文献90

  • 1J Ferlay, F Bray, P Pisani, et al. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No.5[CP/DK]. version 2.0. Lyon: IARC Press, 2004.
  • 2O'Sullivan A, Kocher HM. Pancreatic cancer[J]. Br Med J(Clin Evid), 2007,11:409-437.
  • 3Li D, Xie K, Wolff R, et al. Pancreatic cancer[J]. Lancet, 2004,363(9414): 1049-1057.
  • 4Parkin DM, Chen VW, Ferlay J, et al. Comparability and quality control in cancer registration. IARC Technical Report No 19[M]. Lyon: IARC Press, 1994.
  • 5Jensen OM, Parkin DM, MacLennan R, et al. Cancer registration: principles and methods [M]. Lyon: IARC Scientific Publications, 1991.
  • 6全国肿瘤防治研究办公室.中国肿瘤登记工作指导手册[M].北京:中国协和医科大学出版社,2006.
  • 7Esteve J, Benhamou E, Raymond L. Statistical methods in cancer research, Vol. iV-descriptive epidemiology[M]// IARC Sci Publ No.128. Lyon: IARC, 1994.
  • 8Michaud DS. Epidemiology of pancreatic cancer[J]. Minerva Chit, 2004,59(2):99-111.
  • 9Parkin DM, Whelan S, Ferlay J, et al. Cancer incidence in five continents, Vol. Ⅰ to Ⅷ. IARC CancerBase No.7 [CP/DK]. Lyon: IARC Press, 2005.
  • 10Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1998[J]. CA Cancer J Clin, 1998,48(1):6-29.

共引文献118

同被引文献10

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部